X4 Pharmaceuticals (XFOR) Projected to Post Earnings on Thursday

X4 Pharmaceuticals (NASDAQ:XFOR) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Thursday, May 1st. Analysts expect X4 Pharmaceuticals to post earnings of ($0.14) per share and revenue of $7.03 million for the quarter.

X4 Pharmaceuticals (NASDAQ:XFOR) last released its quarterly earnings results on Tuesday, March 25th. The company reported ($6.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.10) by ($0.90). The company had revenue of $1.43 million for the quarter, compared to analysts’ expectations of $1.07 million. On average, analysts expect X4 Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

X4 Pharmaceuticals Stock Performance

X4 Pharmaceuticals stock opened at $4.35 on Wednesday. X4 Pharmaceuticals has a 12-month low of $4.17 and a 12-month high of $36.60. The company has a market capitalization of $755.43 million, a price-to-earnings ratio of -48.33 and a beta of 0.58. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.89 and a quick ratio of 4.80. The firm’s fifty day moving average price is $8.25 and its 200 day moving average price is $13.43.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in X4 Pharmaceuticals stock. Bank of America Corp DE increased its holdings in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) by 20.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 133,502 shares of the company’s stock after buying an additional 22,485 shares during the period. Bank of America Corp DE owned about 0.08% of X4 Pharmaceuticals worth $98,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 72.03% of the company’s stock.

Analysts Set New Price Targets

XFOR has been the subject of several recent analyst reports. HC Wainwright reissued a “buy” rating and set a $45.00 price objective on shares of X4 Pharmaceuticals in a report on Thursday, March 27th. Cantor Fitzgerald reissued an “overweight” rating and set a $90.00 price objective on shares of X4 Pharmaceuticals in a report on Wednesday, March 26th.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.